SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Evotec AG. (9/29/11). "Press Release: Acquisition of Remaining 30% of Indian Joint Venture from DIL". Hamburg.

Organisation Organisation Evotec (India) Pvt. Ltd. (RSIPL)
  Group Evotec (Group)
Products Product medicinal chemistry
  Product 2 drug discovery services
Index terms Index term DIL–Evotec: investment, 201109 acquisition €1.7m in cash remaining 30% of Evotec (India) Pvt Ltd (RSIPL) from DIL Ltd
  Index term 2 DIL–Evotec: investment, 200908 acquisition €2.8m cash incl potential earnout for 70% of RSIPL from DIL Ltd
Persons Person Bond, Colin (Vifor Pharma 201707 CFO before Evotec 201008–201606 CFO LEFT 6/16)
  Person 2 Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has signed a Share Purchase Agreement to acquire the remaining 30% of equity of its Joint Venture with DIL Limited, India for €1.7M.

The acquisition of DIL's 30% outstanding equity in the joint venture will give Evotec 100% ownership of this subsidiary. Evotec acquired 70% of the equity of Research Support International Private Limited (RSIPL), in August 2009 which was subsequently renamed Evotec (India) Private Limited. The transaction is anticipated to close on 4th October.

With its now 100% owned Indian subsidiary Evotec has successfully expanded its global scientific resource to offer the most complete and cost efficient drug discovery solutions to the pharmaceutical and biotech industry. Operating out of Thane, Mumbai, Evotec India has 140 scientists, focusing primarily on Medicinal Chemistry. Going forward the intention is to further grow and expand this capacity.

Colin Bond, Chief Financial Officer of Evotec stated: "With the purchase of the remaining 30% of our successful Indian Joint Venture, Evotec is now able to operate and accelerate this business with full control. This transaction will allow financial optimization and a significant reduction in administration. The deal also gives Evotec complete freedom to expand its activity in India in future without any restrictions. The access to a global best quality talent pool is the strategic reason for Evotec to establish operations in India. We would like to thank our friends at DIL for supporting us over the last two years and wish them well as they pursue new business avenues".

Despite the fact that Evotec pays in cash, the company keeps it cash guidance of more than €60 Mio by year end.

Contact Evotec AG:

Dr Werner Lanthaler
Chief Executive Officer
Phone: +49.(0)40.56081-242

Forward-Looking Statements - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Record changed: 2019-06-09


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Evotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top